| Outcome Measures: |
Primary: Change of Soluble Klotho, The blood levels of soluble Klotho will be quantified at baseline after one month and after two month of treatments with Empagliflozine, up to 2 months | Secondary: Change of Fibroblast growth factor 23 (FGF23), The blood levels of FGF23 will be quantified at baseline after one month and after two month of treatment with Empagliflozine, up to 2 months|Change of 1,25 (OH)Vit D, The blood levels of 1,25 (OH)Vit D will be quantified at baseline after one month and after two month of treatment with Empagliflozine, up to 2 months|Change of Parathyroid Hormone (PTH), The blood levels of PTH will be quantified at baseline after one month and after two month of treatment with Empagliflozine, up to 2 months|Change of Glomerular Filtration Rate (eGFR), The levels of eGFR will be quantified at baseline after one month and after two month of treatment with Empagliflozine, up to 2 months|Change of Blood Chemistry, The blood chemistry will be quantified at baseline after one month and after two month of treatment with Empagliflozine, up to 2 months|Change of HbA1c, HbA1c will be quantified at baseline after one month and after two month of treatment with Empagliflozine, up to 2 months
|
